• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在息肉样脉络膜血管病变眼中,经低能量光动力治疗后,通过局灶性黄斑视网膜电图评估黄斑功能。

Macular function evaluated by focal macular electroretinograms after reduced fluence photodynamic therapy in eyes with polypoidal choroidal vasculopathy.

作者信息

Machida Shigeki, Nishimura Tomoharu, Tamada Kunifusa, Harada Tomomi, Kurosaka Daijiro

机构信息

Department of Ophthalmology, Iwate Medical University School of Medicine, Morioka, Iwate, Japan.

出版信息

Doc Ophthalmol. 2012 Apr;124(2):91-8. doi: 10.1007/s10633-011-9307-9. Epub 2011 Dec 31.

DOI:10.1007/s10633-011-9307-9
PMID:22209990
Abstract

The purpose of this study was to evaluate the macular function by measuring the focal macular electroretinograms (ERGs) recorded before and after reduced fluence photodynamic therapy (RFPDT) in patients with polypoidal choroidal vasculopathy (PCV). Eleven eyes of 11 patients with PCV were studied. Their ages ranged from 62 to 85 years with a mean of 74.7 ± 6.9 years. The exposure time for the RFPDT was reduced to 42 s, so that the total energy of the laser was approximately one-half that of the standard PDT. We measured the visual acuity, foveal thickness, and focal macular ERGs before and after the RFPDT. The follow-up period ranged from 13 to 34 months with a mean of 26 months after the treatment. A significant recovery of vision was seen even at 1 week after the RFPDT (P < 0.005), and the visual acuities improved gradually thereafter (P < 0.0005). The foveal thickness was significantly reduced at 1 week after the treatment (P < 0.005) and then continued to become significantly thinner with time (P < 0.0001). A slight recovery of the a- and b-wave amplitudes was seen postoperatively without a transient reduction in the amplitudes. The b-wave amplitude was significantly larger at 3 months after the treatment than at baseline (P < 0.05). Choroidal hypoperfusion did not develop 3 months postoperatively in the indocyanine green angiograms. Exudative changes recurred in 4 (27%) eyes after 1 year and in 9 (82%) eyes during the follow-up period. RFPDT provided short-term benefits in selected patients with PCV with small lesions. The macular function was retained after RFPDT without a transient decrease in visual function. Further study is needed to determine the long-term efficacy of RFPDT for eyes with PCV.

摘要

本研究的目的是通过测量息肉样脉络膜血管病变(PCV)患者在低能量光动力疗法(RFPDT)前后记录的黄斑局部视网膜电图(ERG)来评估黄斑功能。对11例PCV患者的11只眼进行了研究。他们的年龄在62岁至85岁之间,平均年龄为74.7±6.9岁。RFPDT的曝光时间缩短至42秒,使激光的总能量约为标准光动力疗法的一半。我们在RFPDT前后测量了视力、黄斑中心凹厚度和黄斑局部ERG。治疗后的随访期为13至34个月,平均为26个月。即使在RFPDT后1周也可见视力显著恢复(P<0.005),此后视力逐渐改善(P<0.0005)。治疗后1周黄斑中心凹厚度显著降低(P<0.005),然后随时间继续显著变薄(P<0.0001)。术后可见a波和b波振幅略有恢复,且振幅无短暂降低。治疗后3个月b波振幅显著大于基线(P<0.05)。吲哚菁绿血管造影显示术后3个月未发生脉络膜灌注不足。1年后4只眼(27%)出现渗出性改变复发,随访期间9只眼(82%)出现复发。RFPDT为选定的小病灶PCV患者提供了短期益处。RFPDT后黄斑功能得以保留,视觉功能无短暂下降。需要进一步研究以确定RFPDT对PCV眼的长期疗效。

相似文献

1
Macular function evaluated by focal macular electroretinograms after reduced fluence photodynamic therapy in eyes with polypoidal choroidal vasculopathy.在息肉样脉络膜血管病变眼中,经低能量光动力治疗后,通过局灶性黄斑视网膜电图评估黄斑功能。
Doc Ophthalmol. 2012 Apr;124(2):91-8. doi: 10.1007/s10633-011-9307-9. Epub 2011 Dec 31.
2
One-year outcomes of photodynamic therapy in age-related macular degeneration and polypoidal choroidal vasculopathy in Japanese patients.日本患者年龄相关性黄斑变性和息肉样脉络膜血管病变的光动力疗法一年期疗效
Ophthalmology. 2008 Jan;115(1):141-6. doi: 10.1016/j.ophtha.2007.02.031. Epub 2007 Jun 20.
3
Short-term focal macular electroretinogram of eyes treated by aflibercept & photodynamic therapy for polypoidal choroidal vasculopathy.阿柏西普联合光动力疗法治疗息肉样脉络膜血管病变患者眼部的短期局灶性黄斑视网膜电图
Graefes Arch Clin Exp Ophthalmol. 2017 Mar;255(3):449-455. doi: 10.1007/s00417-016-3468-x. Epub 2016 Aug 18.
4
Reduced-fluence photodynamic therapy and anti-vascular endothelial growth factor for polypoidal choroidal vasculopathy in an Indian population.印度人群中低能量光动力疗法联合抗血管内皮生长因子治疗息肉样脉络膜血管病变
Indian J Ophthalmol. 2016 Dec;64(12):908-913. doi: 10.4103/0301-4738.198856.
5
Comparing efficacy of reduced-fluence and standard-fluence photodynamic therapy in the treatment of polypoidal choroidal vasculopathy.比较低强度与标准强度光动力疗法治疗息肉样脉络膜血管病变的疗效。
BMC Ophthalmol. 2020 Apr 15;20(1):150. doi: 10.1186/s12886-020-01419-8.
6
Long-term efficacy and safety of verteporfin photodynamic therapy in combination with anti-vascular endothelial growth factor for polypoidal choroidal vasculopathy.抗血管内皮生长因子药物联合光动力疗法治疗息肉状脉络膜血管病变的长期疗效和安全性。
Indian J Ophthalmol. 2018 Aug;66(8):1119-1127. doi: 10.4103/ijo.IJO_1222_17.
7
Selective photodynamic therapy for neovascular age-related macular degeneration with polypoidal choroidal neovascularization.用于治疗伴有息肉样脉络膜新生血管的新生血管性年龄相关性黄斑变性的选择性光动力疗法
Retina. 2007 Sep;27(7):825-31. doi: 10.1097/IAE.0b013e31804b3f70.
8
Photodynamic therapy with verteporfin for symptomatic polypoidal choroidal vasculopathy: one-year results of a prospective case series.维替泊芬光动力疗法治疗症状性息肉状脉络膜血管病变:一项前瞻性病例系列研究的一年结果
Ophthalmology. 2004 Aug;111(8):1576-84. doi: 10.1016/j.ophtha.2003.12.056.
9
Photodynamic therapy with verteporfin for polypoidal choroidal vasculopathy of the macula.维替泊芬光动力疗法治疗黄斑息肉样脉络膜血管病变
Ophthalmologica. 2004 May-Jun;218(3):193-201. doi: 10.1159/000076844.
10
Focal macular electroretinograms after photodynamic therapy combined with posterior juxtascleral triamcinolone acetonide.
Retina. 2009 Jun;29(6):803-10. doi: 10.1097/IAE.0b013e31819c631a.

引用本文的文献

1
Microperimetry and multimodal imaging in polypoidal choroidal vasculopathy.微视野检查和多模态成像在息肉样脉络膜血管病变中的应用。
Sci Rep. 2018 Oct 25;8(1):15769. doi: 10.1038/s41598-018-33781-5.
2
One-year results of intravitreal ranibizumab combined with reduced-fluence photodynamic therapy for polypoidal choroidal vasculopathy.玻璃体内注射雷珠单抗联合低能量光动力疗法治疗息肉状脉络膜血管病变的一年结果
Clin Ophthalmol. 2014 Jan 28;8:235-41. doi: 10.2147/OPTH.S54578. eCollection 2014.

本文引用的文献

1
Three-year follow-up results of photodynamic therapy for polypoidal choroidal vasculopathy.光动力疗法治疗息肉状脉络膜血管病变的 3 年随访结果。
Jpn J Ophthalmol. 2011 Jan;55(1):39-44. doi: 10.1007/s10384-010-0886-x. Epub 2011 Feb 18.
2
One-year results of reduced-fluence photodynamic therapy for polypoidal choroidal vasculopathy.减少强度的光动力疗法治疗息肉样脉络膜血管病变的一年疗效。
Am J Ophthalmol. 2010 Mar;149(3):465-71.e1. doi: 10.1016/j.ajo.2009.09.020. Epub 2009 Dec 30.
3
Focal macular electroretinograms after photodynamic therapy combined with posterior juxtascleral triamcinolone acetonide.
Retina. 2009 Jun;29(6):803-10. doi: 10.1097/IAE.0b013e31819c631a.
4
Long-term results of photodynamic therapy of polypoidal choroidal vasculopathy.息肉状脉络膜血管病变光动力疗法的长期结果
Retina. 2008 May;28(5):717-22. doi: 10.1097/IAE.0b013e31816577cb.
5
Guidelines for PDT in Japan.
Ophthalmology. 2008 Mar;115(3):585-585.e6. doi: 10.1016/j.ophtha.2007.10.018.
6
Role of photodynamic therapy in polypoidal choroidal vasculopathy.光动力疗法在息肉样脉络膜血管病变中的作用。
Jpn J Ophthalmol. 2007 Jul-Aug;51(4):270-7. doi: 10.1007/s10384-007-0452-3. Epub 2007 Aug 3.
7
One-year outcomes of photodynamic therapy in age-related macular degeneration and polypoidal choroidal vasculopathy in Japanese patients.日本患者年龄相关性黄斑变性和息肉样脉络膜血管病变的光动力疗法一年期疗效
Ophthalmology. 2008 Jan;115(1):141-6. doi: 10.1016/j.ophtha.2007.02.031. Epub 2007 Jun 20.
8
Clinical characteristics of exudative age-related macular degeneration in Japanese patients.日本患者渗出性年龄相关性黄斑变性的临床特征
Am J Ophthalmol. 2007 Jul;144(1):15-22. doi: 10.1016/j.ajo.2007.03.047. Epub 2007 May 23.
9
Correlation between focal macular electroretinograms and angiographic findings after photodynamic therapy.光动力疗法后黄斑区局部视网膜电图与血管造影结果的相关性
Invest Ophthalmol Vis Sci. 2007 May;48(5):2254-9. doi: 10.1167/iovs.06-1277.
10
Subtype lesions of neovascular age-related macular degeneration in Chinese patients.中国患者新生血管性年龄相关性黄斑变性的亚型病变
Graefes Arch Clin Exp Ophthalmol. 2007 Oct;245(10):1441-5. doi: 10.1007/s00417-007-0575-8. Epub 2007 Apr 4.